Minimal Residual Disease Remains An Evolving and Game-Changing Field
MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.
A Step Forward in Treating KRAS G12-Mutated Lung Cancer
Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.
Some Immunity Is Better Than None Against COVID-19
Many things can influence a patient’s response to the COVID-19 vaccine, such as their treatments or whether they have a higher tumor burden.
Examining Racial and Ethnic Disparities in Cancer Care
The past year has spotlighted racial inequities not only in the U.S., but worldwide. It has also opened our eyes as to how a major health disruption — in this case, a pandemic — can aggravate the unacceptable status quo.
Metastatic Breast Cancer: The Future is Now
In this issue of CURE magazine, we review the current approaches for the evaluation and treatment of metastatic breast cancer, and what the future holds.
A Worthwhile Investment
Receiving a cancer diagnosis is a turning point, a moment at which patients need to start determining what seems like the right treatment path and exerting their best efforts to make it happen.
More Than a Buzzword, Immunotherapy Holds Great Promise
Immunotherapy â€“ it's the buzzword of the moment. It would be difficult to imagine an area of the field generating more excitement and hope than immuno-oncology is sparking right now.
Resolving a Controversy: The Value of PSA Screening
Medical and scientific communities continue to weigh the value of PSA screening
A Cultural and Scientific Tug of War
Throughout the history of medicine, there has been an intriguing interplay between pop culture and science.
Crossing the Divide
Understanding how the immune system controls itself has led to advances in immunotherapy.
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
Sorting out the low-risk cancers
ASCO: Early studies show promise in treating metastatic breast cancer
ASCO: More answers, and questions, on best hormonal therapy for early-stage breast cancer
ASCO: Study shows Herceptin still best bet in HER2-positive, early-stage breast cancer
ASCO: Bone-strengthening drugs could be given less frequently in metastatic breast cancer
Why ASCO matters
AACR update: Breast cancer studies offer more potential treatment options
AACR update: New immunotherapy drug shows benefit in lung cancer
Bisphosphonates to prevent breast cancer recurrence
SABCS: Advances in hormone therapies for ER-positive breast cancer
An introduction to SABCS 2013: HER2-positive therapies before surgery
Perjeta approval becomes a milestone in drug development
Redefining the word "cancer"
Making sense of epidemiological studies: Living with knowledge or fear?
Whose genome is it anyway?
From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer
From ASCO: Updates in HER2-positive breast cancers
Is advanced breast cancer really increasing in younger women?
Personalized medicine and what it means
2 Clarke Drive Cranbury, NJ 08512